Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 3
2(33.3%)
6Total
Phase 2(4)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00258336Phase 2Unknown

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Role: lead

NCT00324831Phase 3Suspended

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Role: lead

NCT00089115Phase 3Terminated

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Role: lead

NCT00104819Phase 2Terminated

Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

Role: lead

NCT00041730Phase 2Unknown

Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma

Role: lead

NCT00036426Phase 2Unknown

Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

Role: lead

All 6 trials loaded